Formulation and Evaluation of Orodispersible Tablet of Sulindac
European Journal of Pharmaceutical Research · 2022
DOI: 10.24018/ejpharma.2022.2.3.41 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmaceutical Research, 2022. Verfasst von Bhavna B. Gaikwad und 2 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Oral administration of dosage form is the most recommended mode of administration, because of its self-medication, accurate dose of the drug, and ease of administration. However, trouble swallowing in geriatric patients is one major negative of this route, which can mentally disrupt patients. The goal of this study was to use the direct compression method to make orodispersible tablets of sulindac utilizing various doses of super disintegrant agents such as Sodium starch glycolate Crospovidone and Croscarmellose sodium. Three distinct super disintegrants were used to create nine formulations with varying concentration levels. The preformulation, precompression, and post-compression properties of the powder combinations were assessed. In comparison to the other formulations, tablets from batch F3 containing crospovidone had superior organoleptic qualities, as well as outstanding drug release and in-vitro disintegration time. The super disntegrants addition technique was shown to be a viable method for manufacturing orodispersible tablets using the direct compression method.
Zitieren
APA
Gaikwad, B. B., Rane, B. R., & Jain, A. S. (2022). Formulation and Evaluation of Orodispersible Tablet of Sulindac. European Journal of Pharmaceutical Research. https://doi.org/10.24018/ejpharma.2022.2.3.41
Vancouver
Gaikwad BB, Rane BR, Jain AS. Formulation and Evaluation of Orodispersible Tablet of Sulindac. European Journal of Pharmaceutical Research. 2022. doi:10.24018/ejpharma.2022.2.3.41
BibTeX
@article{Gaikwad2022,
author = {Gaikwad, Bhavna B. and Rane, Bhushan R. and Jain, Ashish S.},
title = {Formulation and Evaluation of Orodispersible Tablet of Sulindac},
journal = {European Journal of Pharmaceutical Research},
year = {2022},
doi = {10.24018/ejpharma.2022.2.3.41}
}
EUVIMED